A strange heart

Abstract

24 Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005;112:2769–77. 25 Blok M, Boukens BJ. Mechanisms of arrhythmias in the Brugada syndrome. Int J Mol Sci 2020;21:7051–20. 26 Hoogendijk MGet al. The Brugada ECG pattern a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ. Arrhythmia Electrophysiol 2010;3:283–90. 27 Catalano O, Antonaci S, Moro G, et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J 2009;30:2241–8. 28 Nademanee K, Raju H, de Noronha SV, et al. Fibrosis, connexin43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol 2015;66:1976–86. 29 Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm 2016;13:1274–82. 30 Michowitz Y, Milman A, SarquellaBrugada G, et al. Feverrelated arrhythmic events in the multicenter survey on arrhythmic events in Brugada syndrome. Heart Rhythm 2018;15:1394–401. 31 Chung FP, Raharjo SB, Lin YJ, et al. A novel method to enhance phenotype, epicardial functional substrates, and ventricular tachyarrhythmias in Brugada syndrome. Heart Rhythm 2017;14:508–17. 32 Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:602–7. 33 Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061–70. 34 Jons C, Gollob MH. Brugada syndrome: Let’s talk about sex. Heart Rhythm 2018;15:1466–7. 35 Sacher F, Probst V, Maury P, et al. Outcome after implantation of a cardioverterdefibrillator in patients with Brugada syndrome: a multicenter studypart 2. Circulation 2013;128:1739–47. 36 Raju H, Papadakis M, Govindan M, et al. Low prevalence of risk markers in cases of sudden death due to Brugada syndrome relevance to risk stratification in Brugada syndrome. J Am Coll Cardiol 2011;57:2340–5. 37 Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation 2016;133:622–30. 38 Honarbakhsh S, Providencia R, Lambiase PD. Risk stratification in Brugada syndrome: current status and emerging approaches. Arrhythm Electrophysiol Rev 2018;7:79. 39 Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in lossoffunction sodium channelopathies. Heart Rhythm 2009;6:341–8. 40 AlKhatib SMet al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2018;138:e272–391. 41 Tadros R, Tan HL, Mathari SE. Predicting cardiac electrical response to sodiumchannel blockade and Brugada syndrome using polygenic risk scores. Eur Heart J 2019;40:3097–107. 42 Honarbakhsh S, Providencia R, GarciaHernandez J, et al. A primary prevention clinical risk score model for patients with Brugada syndrome (BRUGADARISK). JACC Clin Electrophysiol 2021;7:210–22. 43 Probst V, Goronflot T, Anys S, et al. Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. Eur Heart J 2021;42:1687–95. 44 Wu CI, Postema PG, Arbelo E, et al. SARSCoV2, COVID19, and inherited arrhythmia syndromes. Heart Rhythm 2020;17:1456–62. 45 Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by Hrs, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;10:193263. 46 Olde Nordkamp LRA, Vink AS, Wilde AAM, et al. Syncope in Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic from nonarrhythmic causes. Heart Rhythm 2015;12:367–75. 47 Brignole M, Moya A, Lange FJde. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39. 48 Gonzalez Corcia MC, Sieira J, Pappaert G, et al. Implantable CardioverterDefibrillators in Children and Adolescents With Brugada Syndrome. J Am Coll Cardiol 2018;71:148–57. 49 Viskin S, Wilde AAM, Krahn AD, et al. Inaccessibility to quinidine therapy is about to get worse. J Am Coll Cardiol 2013;62:355. 50 Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2017;10:1–13.